Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.84)
# 3,695
Out of 4,842 analysts
35
Total ratings
29.63%
Success rate
-21.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.31 | +1,533.45% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.95 | +235.20% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $24.58 | +34.26% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $2.77 | +188.81% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $20.04 | +149.50% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $42.60 | -31.92% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $8.66 | +73.21% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $10.64 | +191.35% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $30.25 | +98.35% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $103.06 | +35.84% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.58 | +216.46% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.32 | +204.18% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.50 | +633.33% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.25 | +940.00% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $17.02 | +46.89% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.31 | +1,536.13% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.13 | +838.97% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.31
Upside: +1,533.45%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.95
Upside: +235.20%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.58
Upside: +34.26%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $2.77
Upside: +188.81%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $20.04
Upside: +149.50%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $42.60
Upside: -31.92%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $8.66
Upside: +73.21%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $10.64
Upside: +191.35%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $30.25
Upside: +98.35%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $103.06
Upside: +35.84%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.58
Upside: +216.46%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.32
Upside: +204.18%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.50
Upside: +633.33%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.25
Upside: +940.00%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $17.02
Upside: +46.89%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.31
Upside: +1,536.13%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.13
Upside: +838.97%